Bristol Myers Squibb launches heart medication Kopozgo in Indian market (Soban News)

Kopozgo is the first and only oral, selective cardiac myosin inhibitor approved in India for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), the company said​Kopozgo is the first and only oral, selective cardiac myosin inhibitor approved in India for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), the company said ​Home Page [ SOBAN NEWS: International and National ]